Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367613 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment Extension of Protocol MNTX 302
A Phase 3 study of Terminal Illness, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT01367613: Completed Phase 3 study of Terminal Illness, sponsored by Bausch Health Americas.
NCT01367613 is a Phase 3 study of Terminal Illness that has completed, run by Bausch Health Americas. The registered enrollment target is 89 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01367613, a Phase 3 study of Terminal Illness, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
Primary Outcome
To provide access to treatment with MNTX, administered SC, to patients who completed Progenics' Protocol MNTX 302
Conditions Studied
Interventions
- DRUG SC Methylnaltrexone
Study Locations (1)
New York
- Progenics Pharmaceuticals, Inc. - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT01367613 record still lists
NCT01367613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Terminal Illness appearing as the primary indexed condition, and to 1 intervention - of which SC Methylnaltrexone is the first listed.
NCT01367613 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01367613 about?
NCT01367613 is a clinical study titled "Open-Label Treatment Extension of Protocol MNTX 302". This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
What is the current status of trial NCT01367613?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2004-03. Estimated completion is 2006-01.
What conditions does trial NCT01367613 study?
This clinical trial studies the following conditions: Terminal Illness.
What interventions are being tested in trial NCT01367613?
The interventions under investigation include: SC Methylnaltrexone (DRUG).
Who is sponsoring clinical trial NCT01367613?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01367613 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Terminal Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01367613's enrollment target sits among peer trials
89 1738th of 2000 higher than 262 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia